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Abstract 
The human eukaryotic release factor 3a (eRF3a), encoded by the G1 to S phase 
transition 1 gene (GSPT1; alias eRF3a), is upregulated in various human cancers. GSPT1 
contains a GGCn polymorphism in exon 1, encoding a polyglycine expansion in the N-
terminal of the protein. The longer allele, GGC12, was previously shown to be 
associated to cancer. The GGC12 allele was present in 2.2% of colorectal cancer 
patients but was absent in Crohn disease patients and in the control group. Real-time 
quantitative RT-PCR analysis showed that the GGC12 allele was present at up to 10-fold 
higher transcription levels than the GGC10 allele (P < 0.001). No GSPT1 amplifications 
were detected, and there was no correlation between the length of the alleles and 
methylation levels of the CpG sites inside the GGC expansion. Using flow cytometry, 
we compared the levels of apoptosis and proliferation rates between cell lines with 
different genotypes, but detected no significant differences. Finally, we used a 
cytokinesis-block micronucleus assay to evaluate the frequency of micronuclei in the 
same cell lines. Cell lines with the longer alleles had higher frequencies of micronuclei 
in binucleated cells, which is probably a result of defects in mitotic spindle formation. 
Altogether, these findings indicate that GSPT1 should be considered a potential proto-
oncogene. 
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